Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Tetravalent HPV Vaccine (Hansenula Polymorpha) in Healthy Chinese Subjects
NCT02888418Phase 1Unknown
- Sponsor
- Beijing Chaoyang District Center for Disease Control and Prevention
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of CERVAVAC in Cervical Cancer (CC) and human papillomavirus infection (6 arms), sponsored by Beijing Chaoyang District Center for Disease Control and Prevention. Primary endpoint: Rate of Adverse reactions at 30 days. Status: unknown.
02
Drugs
CERVAVAC
03
Conditions
Cervical Cancer (CC)human papillomavirus infection
Beyond the preview
Go deeper on NCT02888418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888418.